Get my own profile
Public access
View all95 articles
3 articles
available
not available
Based on funding mandates
Co-authors
- David ToughGSKVerified email at gsk.com
- Frank S WalshCEO OssianixVerified email at ossianix.com
- Paul Peter TakCandel Therapeutics, GlaxoSmithKline, Kintai Therapeutics, Academic Medical Center, AmsterdamVerified email at candeltx.com
- Gerard DrewesCellzome/GlaxoSmithKline R&DVerified email at gsk.com
- Marcus BantscheffCellzome, a GSK companyVerified email at gsk.com
- Scott DewellSenior Director, Biodevelopment - CepheidVerified email at cepheid.com
- kouzaridesUniversity of CambridgeVerified email at gurdon.cam.ac.uk
- Ben GarciaAssociate Professor, University of Pennsylvania School of MedicineVerified email at mail.med.upenn.edu
- Samuel RobsonProfessor of Genomics and BioinformaticsVerified email at port.ac.uk
- Kate JeffreyVP, Immune Therapeutics Discovery, Moderna. Formerly Harvard Medical School; Massachusetts GeneralVerified email at mgh.harvard.edu
- Isabelle BecherEMBL HeidelbergVerified email at embl.de
- Paul WilsonScientific Investigator GSKVerified email at gsk.com
- Andrew J BannisterSenior Research Associate, Gurdon Institute, University of CambridgeVerified email at cam.ac.uk
- Or Gozani, M.D., Ph.D.Morris Herzstein Professor of Biology, Stanford UniversityVerified email at stanford.edu
- Edward HookwayNHSVerified email at nhs.net
- Peter TumminoChief Scientific Officer, Nimbus TherapeuticsVerified email at nimbustx.com
- Jessica Sook Yuin HoDuke-NUS medical schoolVerified email at duke-nus.edu.sg
- Mikhail SavitskiEMBLVerified email at embl.de
- Minna U KaikkonenAdjunct professor, University of Eastern FinlandVerified email at uef.fi
- glass ckProfessor Cellular and Molecular Medicine UC San DiegoVerified email at ucsd.edu